VivoSim NAMkind platform featured in presentation at DDW

VivoSim (VIVS) Labs announces its NAMkind platform for liver toxicology, provided as a commercial service to pharma companies, was featured in an oral presentation at the Digestive Disease Week, DDW, Conference showing best-in-class predictive power against a set of test liver compounds. VivoSim’s liver predictive power was shown to be 87.5% for a set of challenging liver toxicity cases – inclusive of classic cases of “liver tox misses” drugs with unforeseen liver toxicity found in clinical trials or drugs that were withdrawn from the market after liver toxicity issues emerged later. The platform identified correctly that 87.5% of the known liver-toxic drugs could be seen as liver toxic using NAMkind liver. This is known as the sensitivity of the platform, which at 87.5% is a world’s best. Importantly, the specificity was 100%, meaning that none of the compounds tested that are not liver toxic were incorrectly identified as having liver toxicity issues by the platform.